Our finding that MIBC patients with CCL5-positive ICs have a better prognosis (OS, DSS and RFS) suggests that CCL5 expression in ICs, possibly as a surrogate marker for cytotoxic CD8+ T cells and NK cells, may play a role in the anti-tumor immune response. The gene discussed is CD8A; the disease is neoplasm.